Myriad owns the patent on breast cancer genes and so is the only company that can test for them . Myriad Genetics holds the monopoly on breast cancer genes . Myriad offers one test that catches most cases , then charges $ 100 for second . It defends BART test , based on separate studies .
Myriad Genetics holds the monopoly on breast cancer genes . Myriad offers one test that catches most cases , then charges $ 100 for second . It defends BART test , based on separate studies .